22nd Cardiovascular Clinical Trialists (CVCT) Global Forum

Prof. Asita de Silva, Director of the Clinical Trials Unit, University of Kelaniya Sri Lanka, will join global scientists and trialists at the 22nd CVCT – Cardiovascular Clinical Trialists (CVCT) Global Forum, held from 8–10 December 2025 at The The Mayflower Hotel Washington, D.C.

CVCT is a recognized and respected organization that aims to bring key global experts from multiple backgrounds, including academy, industry R&D, regulatory agencies (FDA, EMA), major journal editors, NHLBI, payers (CMS, HTA organisations) and patient representatives.

Prof. de Silva will present results from the TRIDENT trial in the session Fixed Dose Combination – Polypill Trials, chaired by Prof. Valentin Fuster (Mount Sinai Fuster Heart Hospital & CNIC, USA) and Dr. Oyere Onuma (Mount Sinai, USA).

Other speakers in this session include:
1. Prof. Phil Joseph – McMaster University, Canada
2. Prof. Sheila Martins – World Stroke Organization / Federal University of Rio Grande do Sul, Brazil
3. Prof. Anubha Agarwal – Washington University in St. Louis
4. Dr. Ambarish Pandey – UT Southwestern Medical Center, Baim Institute for Clinical Research
5. Prof. hiddo lambers heerspink – University Medical Center Groningen, Netherlands
6. Dr. Nelson Wang – Brigham and Women’s Hospital
7. Prof. Stefano Taddei – Università di Pisa

🔹 Joining scientific discussions on global polypill adoption
Prof. de Silva will also take part in the Multi-Stakeholder Think Tank Debate alongside:

1. Dr. Ankeet Bhatt – Kaiser Permanente
2. Prof. Habib Gamra– Pan-African Society of Cardiology, Tunisia
3. Prof. Mark Huffman – Washington University in St. Louis
4. Prof. Anthony Rodgers – The George Institute for Global Health
5. Dr. Norman Stockbridge– Former Director, Division of Cardiology and Nephrology, U.S.FDA
6. Prof. Stefano Taddei – Università di Pisa, Italy

This discussion will explore clinical development, regulatory pathways, and access strategies for fixed-dose combination therapies, including insights from public health, regulatory, and industry perspectives.

🔹 Contributing to Asia’s cardiovascular research dialogue
In the CVCT–APAC session on Cardiometabolic Trials in Asia – Unique Considerations, chaired by Prof. Carolyn Lam (Duke-NUS Medical School, Singapore) and Prof. Lijing Yan (Duke Kunshan University, China), Prof. de Silva will speak on “Polypill cardiometabolic trials: Why Asia?”

Panel members include:
1. Dr. Vijay Chopra – Medanta Heart Institute, India
2. Dr. Anders Gabrielsen – Ribocure Pharmaceuticals AB, China
3. Dr. Xinli Li – Nanyang Medical College, China
4. Dr. Peder Myhre – University of Oslo, Norway
5. Prof. Yasuhiko Sakata – Osaka University, Japan
6. Dr. Helena Wang – China Editor, The Lancet
7. Dr. Christine Gouillard – Us2.ai, Singapore

The Forum will bring together experts from academia, regulatory agencies, and industry to align trial design and access strategies across global cardiovascular programs.

Attendees are encouraged to connect with Prof. Asita de Silva during CVCT 2025 to discuss collaborative opportunities in cardiovascular and clinical research.

📍 The The Mayflower Hotel Washington, D.C. | 8–10 December 2025